ArticlePathogens and disease2025
Characterization of BK polyomavirus-associated nephropathy (BKPyVAN) in kidney transplant recipients using transcriptomic analysis: a comprehensive scoping review.
Article in Pathogens and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BK polyomavirus (BKPyV) infection reactivates with immunosuppressive therapies and can lead to the development of BKPyV-associated nephropathy (BKPyVAN) in kidney transplant recipients. This scoping review assesses the use of transcriptomics to profile BKPyVAN in kidney transplant recipients. The following search strategy was employed in Medline and Embase: 'BK virus' or 'BK polyomavirus' or 'Polyomavirus' AND 'Kidney transplant' or 'Nephritis' or 'Nephropathy' AND 'Gene expression' or 'Transcriptomics' or 'mRNA'. The search identified 368 publications (264 EMBASE and 104 MEDLINE), and after removal of duplicates (92) and abstract/full-text screening, there were 11 eligible studies which included 7 original transcriptomic studies and 4 bioinformatic studies. There was consistent dysregulated expression of proinflammatory pathways (e.g. cytokines, chemokines, T- and B-cell-related pathways) in BKPyVAN compared with stable graft function. There was considerable overlap between the gene expression patterns identified in BKPyVAN and T-cell mediated rejection that require more exploration. This review highlights limitations including small sample sizes, lack of validation, and variation in technical platforms and study designs. Transcriptomics in BKPyVAN is currently underutilized and there is a genuine need for further research in larger cohorts to provide action in discovering novel therapeutic targets and discriminative gene expression signatures to guide individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.